Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

Niels Vande Casteele(KU Leuven), Marc Ferrante(KU Leuven), Gert Van Assche(KU Leuven), Vera Ballet(KU Leuven), Griet Compernolle(KU Leuven), Kristel Van Steen(University of Liège), Steven Simoens(KU Leuven), Paul Rutgeerts(KU Leuven), Ann Gils(KU Leuven), Séverine Vermeire(KU Leuven)
Gastroenterology
February 24, 2015
10.1053/j.gastro.2015.02.031
Cited by 868

Abstract

Related Papers

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Filip Baert, Maja Noman, Séverine Vermeire et al.|New England Journal of Medicine|2003|2k
Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility
Andrea Manca, Neil Hawkins, Mark Sculpher|Health Economics|2004|1.1k
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Paul Rutgeerts, Brian G. Feagan, Gary R. Lichtenstein et al.|Gastroenterology|2004|947
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert, Julián Panés|The American Journal of Gastroenterology|2009|663
Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease
Elana Maser, Renata Villela, Mark S. Silverberg et al.|Clinical Gastroenterology and Hepatology|2006|614